Drug Trial Radar · NCT07571135
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
May 2026
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Elisabeth KincaideGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive. To do this, researchers will compare patients who received letermovir with a group of historical patients who received valganciclovir ("mini dose"). Both groups will be on CMV prophylaxis drug for 90 days post-transplant. The main question the study wants to answer is: • Does letermovir work as well as valganciclovir in preventing CMV infections during the first 12 months after a kidney transplant? The study will also look at other important questions: * Is letermovir easier for patients to tolerate than valganciclovir? * How long does it take for a CMV infection to appear in each group? * Are there differences in "breakthrough" CMV infections between the two medications? * For patients who develop CMV that becomes resistant to treatment, are the resistance patterns different between the two groups
Conditions
- CMV Infection
- CMV
- CMV Viremia
- CMV Disease
Interventions
LetermovirDrug
Letermovir 480 mg PO daily or 240 mg PO daily (if on cyclosporine) for 90 days post kidney transplant
Valganciclovir CMV ProphylaxisDrug
Valganciclovir 450 mg PO daily for 90 days post kidney transplant (Historical Control)
Primary outcomes
What the sponsor says the trial is designed to measure.
- CMV InfectionTime frame: 12 months post kidney transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.